News for Ironwood Pharmaceuticals, Inc. (IRWD)

On June 30, 2025, Vanguard Group Inc. executed a significant transaction by acquiring an additional 505,968 shares of Ironwood Pharmaceuticals Inc. (IRWD). This

- The small-cap ETF is struggling, causing investors to head for the exits. - The exodus, combined with deep losses, has slashed the fund’s assets by nearly half.

On March 31, 2025, Pacer Advisors, Inc. (Trades, Portfolio) executed a significant transaction involving Ironwood Pharmaceuticals Inc. The firm reduced its hold

Pacer Advisors, Inc. (Trades, Portfolio) recently increased its investment in Ironwood Pharmaceuticals Inc. by acquiring an additional 450,949 shares at a price

Ironwood Pharmaceuticals (IRWD) has reiterated its U.S. sales forecast for LINZESS, estimating net sales to fall between $800 million and $850 million. Despite

Ironwood Pharmaceuticals (IRWD) reported first-quarter 2025 revenue of $41.1 million, falling short of the expected $56.7 million. The decline in revenue is att

[url="]Ironwood Pharmaceuticals, Inc.[/url] (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living wi

Revenue: $41.14 million, falling short of the estimated $45.98 million.GAAP Net Loss: $37.39 million, with a net loss per share of $0.23, compared to a net los

Ironwood Pharmaceuticals (IRWD) reported a Q1 2025 total revenue of $41.1 million, a 45% drop year-over-year. The company raised its adj

Ironwood Pharmaceuticals (IRWD) reports Q1 results: Non-GAAP EPS of -$0.14, revenue down 45.1% YoY to $41.14M.

[url="]Ironwood Pharmaceuticals, Inc.[/url] (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Co

Key Highlights for Investors:\n Ironwood Pharmaceuticals (IRWD) faces a setback with FDA requiring another phase 3 trial for apraglutide. The stock dipped 31%,

Ironwood Pharmaceuticals (IRWD) has been downgraded by Craig-Hallum from \

Jefferies has revised its rating for Ironwood Pharmaceuticals (IRWD), downgrading the stock from Buy to Hold. This decision comes in the wake of the U.S. Food a

Ironwood Pharmaceuticals (IRWD) experienced a significant drop in its stock price, falling by 31% to $0.66 during midday trading. The sharp decline came after C

Ironwood Pharmaceuticals (IRWD) faces increased financial challenges as Leerink analyst Faisal Khurshid adjusted the company's price target downward from $3 to

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday. The Dow traded up 0.43% to 40,384.20 while t...

Key Takeaways: Ironwood Pharmaceuticals (IRWD) is assessing strategic paths following a regulatory setback. The FDA's requirement for an additional Phase

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 2% on Monday. The Dow traded up 0.99% to 40,610.00 while the NASDAQ gained 2.0...